(Reuters) -Novo Nordisk expects global sales to decline by low-single-digit percentage in 2026 after the drugmaker unveiled a deal on Thursday to slash prices of popular GLP-1 weight‑loss drugs for U.S. government-backed insurance programs and cash payers.

(Reporting by Sriparna Roy in Bengaluru; Editing by Leroy Leo)

See Full Page